← FDA DRUG APPROVALS

FDA ANDA · ANDA085180

METHOCARBAMOL

Sponsor: WATSON LABS

APPLICATION
ANDA085180
TYPE
ANDA
ORIGINAL APPROVAL
1976-08-26
LATEST ACTION
1999-02-01
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

METHOCARBAMOLDiscontinued
METHOCARBAMOL 500MG · TABLET · ORAL

Approval history

1999-02-01Manufacturing (CMC) · Supplement 38AP
1999-02-01Manufacturing (CMC) · Supplement 40AP
1999-02-01Manufacturing (CMC) · Supplement 39AP
1997-10-17Manufacturing (CMC) · Supplement 36AP
1997-10-17Manufacturing (CMC) · Supplement 37AP
1997-10-17Manufacturing (CMC) · Supplement 35AP
1991-11-22Labeling · Supplement 34AP
1989-02-06Manufacturing (CMC) · Supplement 33AP
1988-08-16Manufacturing (CMC) · Supplement 32AP
1988-08-16Manufacturing (CMC) · Supplement 30AP
1988-08-16Manufacturing (CMC) · Supplement 29AP
1988-08-16Manufacturing (CMC) · Supplement 31AP
1988-03-11Manufacturing (CMC) · Supplement 27AP
1987-01-13Manufacturing (CMC) · Supplement 23AP
1986-06-02Manufacturing (CMC) · Supplement 24AP
1986-01-10Manufacturing (CMC) · Supplement 22AP
1985-03-26Manufacturing (CMC) · Supplement 21AP
1983-01-18Manufacturing (CMC) · Supplement 15AP
1976-08-26OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →